Stemtech (STEK) Total Non-Current Liabilities (2021 - 2022)
Stemtech's (STEK) quarterly Total Non-Current Liabilities came in at $5.6 million in Q3 2022, up 32.63% year-on-year from $4.2 million in Q3 2021, and up 3415.08% quarter-over-quarter from $160259.0 in Q2 2022.
Stemtech (STEK) Total Non-Current Liabilities (2021 - 2022) Analysis & Trends
Stemtech has disclosed Total Non-Current Liabilities across 2 years of filings, most recently posting $5.6 million for Q3 2022.
- Total Non-Current Liabilities for Q3 2022 came in at $5.6 million, up 32.63% year-over-year; the trailing twelve-month figure through Sep 2022 was $5.6 million (up 32.63% YoY), and the FY2021 annual result was $338530.0, up 1766.41% from the prior year.
- Total Non-Current Liabilities came in at $5.6 million for Q3 2022 at Stemtech, up from $160259.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $5.6 million in Q3 2022 to a low of $160259.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Stemtech | - | - | 354,677.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 5.63 Mn |
| Jun 30, 2022 | 160,259.00 |
| Mar 31, 2022 | 235,025.00 |
| Dec 31, 2021 | 338,530.00 |
| Sep 30, 2021 | 4.25 Mn |